Myricx Bio

About:

Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.

Website: https://myricxbio.com

Top Investors: Eli Lilly, Novo Holdings, British Patient Capital, Abingworth, Sofinnova Partners

Description:

Myricx Bio is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyl transferase (NMT), primarily focusing on oncology and exploring potential applications across other diseases. NMT is an enzyme that modifies key proteins for cancer cell survival with specific lipids. Myricx Bio is developing a pipeline of ADCs using its NMT inhibitor (NMTi) payload platform to address critical unmet needs in oncology. It shows excellent preclinical efficacy and safety across various solid tumor antigens and cancer cell types.